ifosfamide has been researched along with granisetron in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (27.27) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 3 (27.27) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bremer, K; Uhlenbusch, R | 1 |
| Cedar, E; Hählen, K; Pinkerton, CR; Quintana, E | 1 |
| Bacci, G; Beghelli, C; Biolchini, A; Ferrari, S; Forni, C; Loro, L; Mazzei, T; Puggioli, C; Simoni, P; Strazzari, S; Tremosini, M | 1 |
| Hashimoto, R; Ikeda, K; Kurokawa, N; Okamoto, Y; Takagi, T; Takenaka, M; Ueda, T; Uejima, E | 1 |
| Behlendorf, T; Jahn, F; Jahn, P; Jordan, K; Kegel, T; Ruessel, J; Schmoll, HJ; Stein, A | 1 |
1 review(s) available for ifosfamide and granisetron
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
5 trial(s) available for ifosfamide and granisetron
| Article | Year |
|---|---|
[Comparison of the antiemetic effectiveness of granisetron and alizapride plus dexamethasone in cytostatic therapy].
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Cisplatin; Dexamethasone; Drug Therapy, Combination; Etoposide; Female; Granisetron; Humans; Ifosfamide; Indazoles; Male; Middle Aged; Neoplasms; Pyrrolidines; Serotonin Antagonists; Single-Blind Method | 1991 |
A randomized comparison of intravenously administered granisetron versus chlorpromazine plus dexamethasone in the prevention of ifosfamide-induced emesis in children.
Topics: Adolescent; Antiemetics; Chi-Square Distribution; Child; Child, Preschool; Chlorpromazine; Dexamethasone; Drug Therapy, Combination; Granisetron; Humans; Ifosfamide; Infusions, Intravenous; Proportional Hazards Models; Prospective Studies; Safety; Single-Blind Method; Statistics, Nonparametric; Vomiting | 1995 |
The antiemetic efficacy and safety of granisetron compared with metoclopramide plus dexamethasone in patients receiving fractionated chemotherapy over 5 days. The Granisetron Study Group.
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Drug Administration Schedule; Drug Therapy, Combination; Etoposide; Female; Granisetron; Humans; Ifosfamide; Indazoles; Male; Metoclopramide; Middle Aged; Vomiting | 1993 |
Granisetron, tropisetron, and ondansetron in the prevention of acute emesis induced by a combination of cisplatin-Adriamycin and by high-dose ifosfamide delivered in multiple-day continuous infusions.
Topics: Acute Disease; Adolescent; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; Cisplatin; Doxorubicin; Drug Administration Schedule; Extremities; Female; Granisetron; Humans; Ifosfamide; Indoles; Male; Ondansetron; Osteosarcoma; Tropisetron; Vomiting | 2000 |
The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (high-dose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carboplatin; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Etoposide; Female; Granisetron; Humans; Ifosfamide; Male; Melphalan; Middle Aged; Morpholines; Nausea; Neurokinin-1 Receptor Antagonists; Paclitaxel; Treatment Outcome; Vomiting; Young Adult | 2011 |
5 other study(ies) available for ifosfamide and granisetron
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
[Comparison of antiemetic efficacy of 5-HT3 receptor antagonists in orthopedics cancer patients receiving high-dose chemotherapy].
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bone Neoplasms; Cisplatin; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Granisetron; Humans; Ifosfamide; Male; Middle Aged; Nausea; Ondansetron; Osteosarcoma; Prospective Studies; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2007 |